Gemvax & KAEL
Company Details
Status: Public
Employees: 11-50
Location:
Daejeon, South Korea
Type:
sample
Technology:
sample
sample
About: Since 2008, GemVax & KAEL has operated as a cutting-edge research and development company developing proprietary peptide drug, GV1001, for treatment against various cancers and neurodegenerative disease including Alzheimer's disease and Progressive Supranuclear palsy.
The fundamental driving purpose of our innovative pharmaceutical research is to facilitate significant improvements to human life through the introduction of advanced medical technology and innovation rooted in advanced scientific measures.
At GemVax, we take pride in our proactive approach to medical research, and our progressive peptide-drug focused advancements have played a crucial role in the incessant global battle against incurable disease.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Gemvax & KAEL | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.